Icon
+91 94997 68112
Login Register

OTREXUP - (10MG/0.4ML, 15MG/0.4ML, 20MG/0.4ML, 25MG/0.4ML, 7.5MG/0.4ML, 12.5MG/0.4ML, 17.5MG/0.4ML, 22.5MG/0.4ML)

METHOTREXATE None
10MG/0.4ML, 15MG/0.4ML, 20MG/0.4ML, 25MG/0.4ML, 7.5MG/0.4ML, 12.5MG/0.4ML, 17.5MG/0.4ML, 22.5MG/0.4ML
Less Than $1000 mn
None None
None None
None None
Otrexup is a folate analog metabolic inhibitor indicated for the: • Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy. • Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.
Yes
OTREXUP Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.